MARKET

LXEO

LXEO

Lexeo Therapeutics Inc
NASDAQ
9.46
-0.57
-5.64%
Opening 11:49 01/08 EST
OPEN
9.88
PREV CLOSE
10.02
HIGH
10.25
LOW
9.40
VOLUME
186.22K
TURNOVER
--
52 WEEK HIGH
10.99
52 WEEK LOW
1.450
MARKET CAP
690.10M
P/E (TTM)
-3.5000
1D
5D
1M
3M
1Y
5Y
1D
Lexeo Therapeutics Announces Research Collaboration With Johnson & Johnson To Explore Targeted Cardiac Delivery Of AAV Gene Therapy
Benzinga · 4h ago
Lexeo Therapeutics Partners with Johnson & Johnson on Targeted Cardiac Gene Therapy
Reuters · 4h ago
LEXEO THERAPEUTICS ANNOUNCES RESEARCH COLLABORATION TO EXPLORE TARGETED CARDIAC DELIVERY OF AAV GENE THERAPY
Reuters · 4h ago
LEXEO THERAPEUTICS INC - ANNOUNCES RESEARCH COLLABORATION WITH JOHNSON & JOHNSON
Reuters · 4h ago
Weekly Report: what happened at LXEO last week (1229-0102)?
Weekly Report · 3d ago
Weekly Report: what happened at LXEO last week (1222-1226)?
Weekly Report · 12/29/2025 10:17
Raymond James Sees an Attractive Setup in These 2 ‘Strong Buy’ Stocks
TipRanks · 12/25/2025 00:00
Lexeo Therapeutics CEO to Present at J.P. Morgan Healthcare Conference
Reuters · 12/22/2025 12:30
More
About LXEO
Lexeo Therapeutics, Inc. is a clinical-stage genetic medicine company dedicated to transforming healthcare by applying pioneering science to fundamentally change how genetically defined cardiovascular diseases and APOE4-associated Alzheimers disease are treated. Using a stepwise development approach, the Company is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4-associated Alzheimers disease programs. Its pipeline consists of candidates targeting patient populations. Its most advanced cardiovascular product candidate, LX2006 for the treatment of patients with Friedreichs ataxia (FA), cardiomyopathy, is being evaluated in SUNRISE-FA, an ongoing Phase I/II clinical trial. Its second most advanced cardiovascular product candidate, LX2020 for the treatment of arrhythmogenic cardiomyopathy, caused by mutations in the PKP2 gene (PKP2-ACM), received IND clearance from the United States Food and Drug Administration (FDA).

Webull offers Lexeo Therapeutics Inc stock information, including NASDAQ: LXEO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LXEO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LXEO stock methods without spending real money on the virtual paper trading platform.